Abstract
The antimicrobial effects of a new quinolone antimicrobial drug, grepafloxacin (GPFX), on respiratory pathogens as well as its clinical effects and utility were assessed as follows:
The measured MICs of GPFX of 82 isolated strains in respiratory infections were: 0.1 μg/ml for 10 strains of Staphylococcus aureus, 0.39 μg/ml for 17 strains of Streptococcus pneumoniae and 12 strains of Streptococcus sp., 0.78 μg/ml for 6 strains of Klebsiella pneumoniae, 0.78 μg/ml for 4 strains of Acinetobacter calcoaceticus, ≤0.006 μg/ml for 16 strains of Haemophilus sp., 0.012 μg/ml for 4 strains of Moraxella catarrhalis and 3.13 μg/ml for 13 strains of Pseudomonas aeruginosa.
GPFX was administered at a dose of 200 or 300 mg once/day for 7-14 days to 17 patients, including 3 cases of acute pneumonia, 4 cases of mycoplasma pneumonia, 1 case of acute bronchitis, 5 cases of chronic bronchitis, 1 case each of secondary infection to bronchiectasis and bronchial asthma, and 2 cases of secondary infection to pulmonary emphysema.
The clinical results were excellent in 2 cases, effective in 12 cases, and slightly effective in 2 cases (excluding 1 patient who did not visit after the first consultation). Regardingthe dose distribution, all 6 cases in the 200 mg/day group and 8 of 10 cases in the 300 mg/day group responded effectively.
The bacteriological results were as follows: 2 strains of isolated H. influenzae, 1 strain each of M.catarrhalis, S. pneumoniae, and S. aureus disappeared, and 1 strain of P. aeruginosa decreased.
No side effects were observed in any of the patients. Abnormal laboratory findings were observed in 3 patients: a decrease in WBC in one and elevation of eosinophils in two.
